Back to catalogue
№ 038 28 filings · 2021-05-13 → 2026-04-23

BEAZLEY PLC

BEZ
Insurance Market cap £7.6bn Overall fit 380 /1000

Quality specialty insurer at fair price with strong downside protection, but a clear miss on the investor's two highest-weighted criteria: minimal AI-receiver exposure and only moderate operating leverage. The bid optionality is interesting but not a thesis the strategy is built around.

Fair value range 1,200p–1,500p Mid case · £8.1bn
Absolute upside +7.1% vs current market cap
Conviction 3/5 confidence in fair call
Supports the call
  • A-rated Lloyd's franchise with clean segmental disclosure
  • Consistent meet/beat on combined-ratio guidance through cycle
  • Rule 2.7 Announcement (2 March 2026) floors downside
Limits the call
  • Bid terms from 2.7 Announcement not in filing set — key valuation input missing
  • Cyber loss-cost trajectory and IFRS 17 IFIE add interpretation noise
Methodology

Forward P/E (9-11x) on normalised earnings, cross-checked vs specialty Lloyd's peers

In one line · bull case

Disciplined A-rated Lloyd's specialty insurer trading at a fair multiple in a softening cycle, with combined-ratio guidance being upgraded and a Rule 2.7 bid in progress providing downside support.

In one line · biggest risk

A systemic cyber event or sharp deepening of the property/specialty soft cycle would hit one of the largest cyber books in the market while pricing power is fading.

Drivers
AI beneficiary 20 /100
Specialty insurer — buyer of AI internally, not a seller into the AI buildout; cyber line is indirect at best.
Operating leverage 50 /100
Investment-float economics scale well, but claims/acquisition costs dominate and move with premium.
Earnings vs expectations 65 /100
Combined-ratio guidance upgraded mid-2025; consistent meet-or-beat cadence across the period.
Growth momentum 45 /100
Decelerating: flat-to-low-single-digit IWP growth guided for 2025; Bermuda platform underpins 2026+ runway.
Moat 60 /100
Top-tier Lloyd's franchise, A-rated, leading cyber writer, but the line is competitively re-priced annually.
Earnings quality 65 /100
Clear segmental disclosure and loss-development tables; IFRS 17/IFIE adds some complexity.
Management quality 70 /100
Internal CEO succession; £350m placing into 2022 hard market and buybacks in soft market are well-timed; AGM pay dissent is a yellow flag.
Cyclicality 60 /100
Pricing-cycle business: renewal rates swung from +17% in 2022 to -4% in 2025.
Leverage 30 /100
Solvency II >170% target, A-ratings throughout, modest Tier 2 sub-debt; balance sheet is conservative.

BEAZLEY PLC (BEZ) — Equity Research Note

Executive summary

Beazley is a Lloyd's-centric specialty (re)insurer with leadership positions in cyber, D&O, property, marine and political risks, underwriting ~$6.1bn of gross premiums across six Lloyd's syndicates plus US, Irish and Bermudian carriers. Across 2022-2025 the group rode a hard market (gross written premiums +22% in 2022, +13% H1 2023, +7% in 2024) then transitioned into a softening cycle through 2025 with rates -4% and growth slowing to flat-low single digits, but profitability strengthened — undiscounted combined ratio guidance was upgraded from "mid-80s" to "low-80s" at the Q3 2025 update 2025-11-25 Q3 trading. The single most important valuation point today is that the 2026 dividend announcement explicitly references a Rule 2.7 Announcement dated 2 March 2026 2026-03-02 dividend; 2026-04-01 Form 8.3, which signals a firm M&A/scheme transaction is in progress — so any standalone fair-value exercise has to be read alongside that bid backdrop.

Fair value estimate

Methodology: Forward P/E on a normalised earnings estimate, cross-checked against P/BV for an A-rated specialty Lloyd's franchise.

Key assumptions (translated to GBP, using ~$1.25/£):

  • 2025E GWP $6.1bn, net retention ~80% → NEP ~$4.9bn.
  • Undiscounted combined ratio "low 80s" guidance 2025-11-25 → underwriting profit ~$850-900m.
  • Investment income guidance ~3.9% on $11.7bn portfolio → ~$450-600m FY.
  • Implied PBT ~$1.3-1.5bn; net income $1.0-1.2bn (£800-960m at 22% tax and FX).
  • EPS on 601m shares: ~135-160p.
  • Fair forward P/E of 9-11x for an A-rated specialty Lloyd's writer in a softening rate cycle.

Fair value range: 1,200p – 1,500p per share → implied market cap £7,217m – £9,022m (mid £8,120m).

Current share price implied by market cap / shares in issue = £7,674.6m / 601.458m ≈ 1,276p.

vs. fair-value midpoint: +6% upside; vs. range: -6% / +18%. Stock is broadly fair / mildly undervalued on standalone fundamentals, with optionality from the in-progress 2.7 transaction.

Sector context

  • Sector: Financials / Insurance (Non-Life Specialty). Confirmed by ICB classification and Lloyd's-led business model.
  • Quality/leverage profile is above typical sector peers: A-rated across all Lloyd's syndicates, Irish, US and Bermudian carriers; Solvency II ratio target >170%; long track record of disciplined underwriting and active capital management (share buybacks in 2024/25, $292m equity raise in 2020, £350m placing in 2022 to fund hard-market growth).
  • Listed peers: Hiscox (HSX), Lancashire Holdings (LRE), Conduit Re (CRE); also globally Arch Capital (ACGL), Markel, RenaissanceRe as Lloyd's-adjacent specialty comparators.

Investment thesis

  • Cycle-mid quality compounder with proven discipline. Beazley upgraded 2025 combined-ratio guidance from mid-80s to low-80s even as renewal rates turned negative (-4%), demonstrating they are willing to trade volume for margin in a softening market — IWP growth expected flat to low single digits, profitability prioritised 2025-11-25 Q3 trading. This is exactly the cycle behaviour you want to own through a downturn.
  • Optionality from in-progress 2.7 Announcement. The 2 March 2026 Rule 2.7 announcement (referenced in the dividend declaration as defining a "Permitted Dividend") and LMR Partners' Form 8.3 disclosure of long+short CFD positions priced at $12.67 2026-04-01 Form 8.3 confirm an active bid situation. Even absent transaction details, a 2.7 announcement is a firm offer and floors the downside.
  • $500m Bermuda build-out targets alternative-risk-transfer growth from 2026. New platform, regulatory approval pending, intended to enable margin-accretive growth into structurally attractive segments without diluting underwriting discipline 2025-11-25 Q3 trading. Provides a 2026+ growth runway when the rest of the book is at low single digits.

Key risks

  • Cyber loss accumulation / systemic cyber event. Cyber Risks GWP $848m YTD Q3 2025 is one of the largest books in the market; rates have been falling since 2022 despite rising ransomware frequency/severity 2025-11-25 Q3. A catastrophic systemic cyber event (cloud outage, supply-chain attack) would directly hit a leading writer.
  • Catastrophe exposure in a hardening climate. Hurricanes Helene & Milton cost $125-175m net of reinsurance in 2024 2024-11-06 Q3; California wildfires ~$80m in 2024; 2021 Q3 cat losses $125m. Recurring tail risk.
  • Soft-market drag on growth. -4% renewal rate change YTD Q3 2025 and growth at the low end of guidance 2025-11-25; if the soft cycle deepens, top-line and underwriting margins compress simultaneously.

Operating leverage

Insurance is a fundamentally fixed-cost-light, variable-cost-heavy business — claims and acquisition costs scale with premium, so true operating leverage is more limited than software/platform peers. Beazley's H1 2021 disclosure (the only segmental P&L in the filings provided) shows acquisition costs ~27% and admin expenses ~10% of NEP — i.e., expense ratio ~37% 2021-07-26 IFRS H1. Most of the expense base scales with premium volume, so a 10-20% revenue beat in a hard cycle drops through largely via better-than-planned claims experience (a ~5pt combined-ratio improvement on $5bn NEP = ~$250m underwriting profit uplift, but this is driven by claims, not fixed-cost dilution). The clearest operating leverage is on investment income: the $11.7bn portfolio at 3.9% yield throws off ~$460m, and incremental float from premium growth converts at near-100% margin. Net: operating leverage exists but is moderate (50-60 range), not platform-like.

Value-trap signals

None obviously identified. Disclosure is high-quality, capital returns are happening (buybacks 2024/25, growing dividend — 25p interim 2025/26 vs 13.5p in 2023), the franchise is taking margin not volume in the soft cycle, and the 2.7 Announcement provides a take-out floor. Mild yellow flags: AGM vote saw 39% against the LTIP and 28% against the Remuneration Policy 2026-04-23 AGM result, signalling shareholder unease on pay — but not a thesis-breaker.

Earnings vs. expectations

Across the period the filings allow tracking guidance vs. delivered. 2022: FY guidance "high 80s combined ratio" → delivered (per 2023 references) — met. 2023: low 80s undiscounted combined ratio guidance, mid-teens GWP growth → delivered ~9% growth gross / 26% net, low 80s CR — met / mild miss on top-line, beat on profitability. 2024: guided ~80% combined ratio, high-single-digit gross growth → delivered (per 2024 Q3 trading) — met. 2025: started at mid-80s CR guidance, upgraded to low 80s at Q3 2025-11-25beat. Pattern: consistently delivers on or ahead of combined-ratio guidance, occasionally moderates growth language as the cycle softens. Overall: disciplined "meet-to-beat" management cadence — not a serial over-promiser.

Conviction

3 / 5 (moderate).

  • Anchors: clean Lloyd's disclosure, A-rated franchise across multiple carriers, consistent guidance delivery and combined-ratio track record, and a Rule 2.7 announcement provides a real-world floor.
  • Limits: 2026 filings reference a 2.7 Announcement but the bid terms are not in the document set (key valuation input is missing); IFRS 17 transition + IFIE complexity makes earnings comparisons noisier; cyber loss-cost trajectory is genuinely uncertain.

Driver scoring rationale

  • AI beneficiary (low): Beazley is a buyer of AI internally, not a seller into the AI buildout. Cyber line indirectly benefits from rising AI-driven attack surface but valuation flows to AI tooling vendors. Press-mention only — does not count.
  • Operating leverage (moderate): investment-float economics scale well, but claims/acquisition cost ratio dominates and scales with premium.
  • Cyclicality (moderate-high): pricing-cycle business; renewal rates swung from +17% (2022) to -4% (2025).
  • Moat (moderate-strong): top-tier Lloyd's franchise, leading cyber book, A-rated balance sheet, but specialty insurance is competitive and re-priced annually.
  • Leverage (low): Solvency II >170%, A-ratings across carriers, modest sub-debt.
  • Earnings quality (above-average for insurance): clear segmental disclosure, IBNR/loss-development tables provided historically, combined ratio reported on consistent undiscounted basis.
  • Management quality (good): Adrian Cox internal CEO succession; disciplined capital actions (£350m 2022 placing into hard market, buybacks in soft market); AGM dissent on pay tempers this.
  • Growth momentum (decelerating): rate change negative, growth at low end of guidance, but Bermuda build-out supports 2026+.
  • Earnings surprise trend (above average): combined-ratio upgrade in 2025; consistent meet/beat.
Filings consulted · 31

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-04-23Result OF Agm2026-04-23_9534808_result-of-agm.md0.30
  2. 2026-04-01Form 8 3 Beazley Plc Amendment Replacing 8788y2026-04-01_9503748_form-8-3-beazley-plc-amendment-replacing-8788y.md0.70
  3. 2026-03-17Notice OF Agm2026-03-17_9478806_notice-of-agm.md0.30
  4. 2026-03-02Dividend Declaration2026-03-02_9454313_dividend-declaration.md0.30
  5. 2025-11-25Trading Statement2025-11-25_9254596_trading-statement.md0.72
  6. 2025-10-06Notice OF Trading Statement Amp Capital Markets Day2025-10-06_9153333_notice-of-trading-statement-amp-capital-markets-day.md0.81
  7. 2025-04-29Trading Statement2025-04-29_8850460_trading-statement.md0.55
  8. 2025-04-22Result OF Agm2025-04-22_8840340_result-of-agm.md0.20
  9. 2025-03-17Notice OF Agm2025-03-17_8783251_notice-of-agm.md0.20
  10. 2024-11-06Trading Statement2024-11-06_8532061_trading-statement.md0.55
  11. 2024-04-29Trading Statement2024-04-29_8160662_trading-statement.md0.38
  12. 2024-04-25Result OF Agm2024-04-25_8157836_result-of-agm.md0.14
  13. 2024-03-20Notice OF Agm2024-03-20_8098505_notice-of-agm.md0.14
  14. 2023-11-30Capital Markets Day Presentation2023-11-30_7913659_capital-markets-day-presentation.md0.43
  15. 2023-11-07Trading Statement2023-11-07_7864216_trading-statement.md0.38
  16. 2023-11-07Notice OF Capital Markets Day2023-11-07_7865680_notice-of-capital-markets-day.md0.43
  17. 2023-07-27Trading Statement For Six Months TO 30 June 20232023-07-27_7657778_trading-statement-for-six-months-to-30-june-2023.md0.38
  18. 2023-05-12Trading Statement2023-05-12_7523984_trading-statement.md0.21
  19. 2023-04-25Result OF Agm2023-04-25_4196_result-of-agm.md0.07
  20. 2023-03-20Notice OF Agm2023-03-20_7479495_notice-of-agm.md0.07
  21. 2022-11-16Beazley Plc Results OF Placing2022-11-16_7374256_beazley-plc-results-of-placing.md0.17
  22. 2022-11-15Beazley Plc Proposed Placing OF Ordinary Shares2022-11-15_7374001_beazley-plc-proposed-placing-of-ordinary-shares.md0.17
  23. 2022-11-11Trading Statement2022-11-11_7336809_trading-statement.md0.21
  24. 2022-05-18Capital Markets Day Presentation2022-05-18_6930878_capital-markets-day-presentation.md0.24
  25. 2022-05-12Notice OF Capital Markets Day2022-05-12_6840604_notice-of-capital-markets-day.md0.24
  26. 2022-05-06Trading Statement2022-05-06_7195041_trading-statement.md0.21
  27. 2022-03-25Result OF Agm2022-03-25_7056500_result-of-agm.md0.07
  28. 2022-02-23Notice OF Agm2022-02-23_6925949_notice-of-agm.md0.07
  29. 2021-11-05Trading Statement2021-11-05_6661569_trading-statement.md0.21
  30. 2021-07-26Correction Interim Results2021-07-26_6742426_correction-interim-results.md0.23
  31. 2021-05-13Trading Statement2021-05-13_6372162_trading-statement.md0.09

This research note was authored by a large language model after reading 28 regulatory filings published between 2021-05-13 and 2026-04-23. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.